Uveitis as the first symptom in spondyloarthritis and its association with the evolution of the disease. Results from the REGISPONSER registry

• Published in: Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2021-05, Vol.88 (3), p.105136-105136, Article 105136
• Main Authors: Gómez-García, Ignacio, Ladehesa-Pineda, María Lourdes, Puche-Larrubia, María Ángeles, Ortega-Castro, Rafaela, Font-Ugalde, Pilar, Pérez-Guijo, Verónica, Escudero-Contreras, Alejandro, Diaz-Villalón, Gonzalo, López-Medina, Clementina, Collantes-Estévez, Eduardo
• Format: Article
• Language: English
• Subjects: Prognosis; Spondyloarthritis; Uveitis
• ISSN: 1297-319X; 1778-7254
• DOI: 10.1016/j.jbspin.2021.105136

•The prevalence of acute anterior uveitis in the REGISPONSER population was 16.2%.•Patients with acute anterior uveitis as first symptom showed a better function and less structural damage than patients with uveitis after the rheumatic symptoms onset.•The moment of appearance of acute anterior uveitis had no impact on the treatment received. To describe the time of onset of acute anterior uveitis (AAU) relative to the appearance of rheumatic symptoms and to determine its association with the evolution of the spondyloarthritis (SpA) in terms of activity, structural damage, functional ability and treatment. This was a cross-sectional study with data extracted from the REGISPONSER (SpA Registry of the Spanish Rheumatology Society). Thirty-one centres participated, and patients with SpA according to the ESSG criteria were included from 2004 to 2007. Patients were classified according to the time of uveitis appearance with regard to rheumatic symptom onset (before, concomitant with, or after rheumatic symptom onset). We compared the clinical characteristics, disease activity, radiographic damage and functional ability between “AAU before or concomitant with rheumatic symptoms” and “AAU after rheumatic symptoms onset”. Finally, we compared whether the time of appearance of AAU had an impact on the use of conventional and biological disease-modifying antirheumatic drugs (csDMARDs and bDMARDs, respectively). A total of 2367 patients were included in REGISPONSER, with an AAU prevalence of 16.2% (379 patients). Patients with AAU before/concomitant with rheumatic symptom onset (n=59) exhibited better functional ability (BASFI, OR 0.85 [0.73-0.99]) and less structural damage (spinal BASRI, OR 0.88 [0.79-0.99]). Additionally, this group of patients was older at SpA symptom onset (OR 1.05 [1.02-1.09]) and had a shorter diagnosis delay (OR 0.90 [0.84-0.96]) compared patients with AAU after rheumatic symptom onset (n=229). No statistically significant differences in the use of DMARDs were noted (27.9% vs 23.2% for csDMARD use and 15.3% vs 20.3% for bDMARD use in patients with AAU before or concomitant with rheumatic symptom onset vs after rheumatic symptom onset, respectively). Patients presenting with a first episode of AAU before/concomitant with the onset of rheumatic symptoms had less severe disease (better functional ability and less structural damage) and a shorter diagnosis delay; however, the time of AAU onset did not impact the treatments received.